NewsBenzingaAIM ImmunoTech Says Phase 2 DURIPANC Topline Results Expected In Q1 2027, With Additional Clinical And Immune-Response Analyses Anticipated In Q3 2027 AIM ImmunoTech Says Phase 2 DURIPANC Topline Results Expected In Q1 2027, With Additional Clinical And Immune-Response Analyses Anticipated In Q3 2027 Benzinga 2026.11.05 14:19 (GMT+0) Open on Benzinga Other news AI models can be tricked into identifying civilians as military targets by telling them it’s a game Why Nvidia Is Falling Tuesday: Jensen Huang’s Comeback Statement, Congress Hearings, and AI Risks General Motors Plans 20% Boost In Robotics As Factory Costs Rise Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer Therapies McKesson Stock Is a Triple Threat at New All-Time Highs. How to Trade It Here. 'Nvidia stopped disclosing Singapore sales as revenues hit $104B' -FT